Showing results (331-340 of 346) with videos related to

Sort By:
Pageof 35
Blood Cancer Discovery|May 9, 2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell LymphomaNeeraj Y Saini, David M Swoboda, Uri Greenbaum, et al.
Bone Marrow Transplantation|May 17, 2019
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit J Kansagra, Noelle V Frey, Merav Bar, et al.
Blood Advances|August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Nature Reviews. Clinical Oncology|February 20, 2021
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancerDristhi Ragoonanan, Sajad J Khazal, Hisham Abdel-Azim, et al.
Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 22, 2018
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow TransplantationAnkit J Kansagra, Noelle V Frey, Merav Bar, et al.
Transplantation and Cellular Therapy|August 24, 2021
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in AdultsLeland Metheny, Natalie S Callander, Aric C Hall, et al.
Leukemia|October 31, 2022
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patientsMichael Boyiadzis, Mei-Jie Zhang, Karen Chen, et al.
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Blood Advances|September 22, 2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AMLKamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, et al.
Pageof 35